The best regulatory intelligence software for biotech in 2026

For most biotechs the thing they'd actually spend this budget on is an experienced human. That's a rational choice: consultants bring pathway judgment, agency relationships, and someone accountable in the room, none of which a tool provides. On a novel asset with thin precedent, judgment is most of the answer.

The limit is arithmetic. Hours don't scale to reading the last thirty similar programs, so wide public-record scans either become billable line items or quietly don't happen, and the strategy rests on a sample. There's also the budget paradox small companies know well: a five-figure consulting invoice is a familiar approval, a three-figure software line item somehow isn't. Hours are the most expensive way to do document recall and the cheapest way to buy judgment. The strongest setup is both: Rhizome builds the evidence pack, the consultant makes the call.

Worth saying plainly: for high-level pathway orientation, a general assistant is reasonably good, it's already paid for, and a small team will and should use it. Pretending otherwise would insult your experience.

Where it breaks is the half that matters at a decision point. General assistants answer from memory plus the open web, and the review packages, CRLs, and trial records that carry real precedent live in databases a crawler barely sees, much of it scanned, image-only PDF. Their economics can't afford exhaustive research either: consumer users want an answer in seconds, so stopping at a handful of sources is the intended design. What you get is the famous precedent while the complete record stays buried, with citations that don't reliably survive a click. Copilot adds the tenant twist: it keeps handing back your own documents when you asked about the world outside.

The answer isn't a third AI subscription for its own sake. Keep the assistant your team likes and connect Rhizome over MCP: the chat stays where it is, the grounded research runs behind it.

Cortellis's coverage is real, and its change alerts are the feature buyers credit most. If you had a global portfolio and a regulatory department, it would rank higher.

At biotech scale the mismatch is mostly commercial: enterprise custom quote, startup plus annual fees buyers describe as substantial, and a value proposition built around standing coverage of markets you don't operate in yet. Many small teams never seriously evaluate it (their practical alternatives are a consultant or general AI), and that's a reasonable read of the situation.

Someone technical will suggest it, and the demo will work. But the corpus maintenance, OCR pipeline, weekly refresh, and evaluation harness are the actual product, and they cost engineering time forever. Build AI where it differentiates you: an agent that predicts whether your candidate works is core to your IP; your fine-tuned models for design are your IP. Very few biotechs aim to differentiate on regulatory, so spending scarce AI staff there is the one build decision that's hard to defend.